ARCH Venture Fund IX, L.P. — SEC Form 4 filings
SEC reporting owner CIK 1666306. 5 Form 4 filings on record with FilingPulse; latest filed 2026-07-06.
Transaction summary — filings shown
Covers all 5 filings on record, filed 2024-02-12 to 2026-07-06. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 6 legs across 3 filings — 2,506,271 shares, $25,699,980 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 16,000 shares, $39,840 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 12.
- Largest priced transaction: purchase of 488,090 shares @ $25.61 ($12,499,985) in Lyell Immunopharma, Inc., filed 2026-03-09.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Lyell Immunopharma, Inc. (LYEL) | 10% owner | 2 | 1 leg · 488,090 sh · $12,499,985 | — | — |
| Sana Biotechnology, Inc. (SANA) | 10% owner | 1 | 3 legs · 1,818,181 sh · $9,999,996 | — | — |
| Boundless Bio, Inc. (BOLD) | 10% owner | 2 | 2 legs · 200,000 sh · $3,200,000 | 1 leg · 16,000 sh · $39,840 | 12 |
Form 4 filings — ARCH Venture Fund IX, L.P.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-06 | 4 | Boundless Bio, Inc. (BOLD) jointly with ARCH Venture Fund IX Overage, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC | Option exercise (M): 16,000 @ $1.03 · Sale (S): 16,000 @ $2.49 · Option exercise (M): 16,000 (derivative) @ $0 | EDGAR |
| 2026-03-09 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX Overage, L.P. | Purchase (P): 488,090 @ $25.61 | EDGAR |
| 2025-07-29 | 4 | Lyell Immunopharma, Inc. (LYEL) jointly with ARCH Venture Partners IX, LLC, ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Fund IX Overage, L.P., CRANDELL KEITH, BYBEE CLINTON, NELSEN ROBERT | Holdings only — no transactions reported | EDGAR |
| 2024-04-04 | 4 | Boundless Bio, Inc. (BOLD) jointly with ARCH Venture Fund IX Overage, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC | Conversion (C): 589,743 · Conversion (C): 787,545 · Conversion (C): 1,048,433 · Purchase (P): 66,667 @ $16 · Purchase (P): 133,333 @ $16 · Conversion (C): 424,908 (derivative) · +6 more | EDGAR |
| 2024-02-12 | 4 | Sana Biotechnology, Inc. (SANA) jointly with ARCH Venture Fund X, L.P., ARCH Venture Fund X Overage, L.P., ARCH Venture Fund IX Overage, L.P., ARCH Venture Partners IX, L.P., ARCH Venture Partners IX Overage, L.P., ARCH Venture Partners X, L.P., ARCH Venture Partners X Overage, L.P., ARCH Venture Partners IX, LLC, ARCH Venture Partners X, LLC | Purchase (P): 363,637 @ $5.50 · Purchase (P): 727,272 @ $5.50 · Purchase (P): 727,272 @ $5.50 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1666306 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →